Compound ID | 3398
Class: Bacteriophage and/or bacteriophage-derived product
| Agent Type: | Direct acting; Bacteriophage or bacteriphage-derived product; |
| Spectrum of activity: | Gram-negative |
| Target Pathogen: | Active against Shigella sp.; intended indication for Shigellosis |
| Description: | Bacteriophage; contains five double-stranded DNA of Myoviridae and Siphoviridae lytic phages |
| Institute where first reported: | Intralytix |
| Year first mentioned: | 2015 |
| Highest development stage: | Phase 2 (NCT05182749) |
| Development status: | Active |